Betulinic acid as a novel AT1R inhibitor: attenuation of liver fibrosis via modulation of endothelial–mesenchymal transition in chronic hepatic injury
This study presents the first evidence that BA alleviates liver fibrosis by acting as an AT1R antagonist to inhibit EndMT. These findings underscore the potential therapeutic application of BA as an AT1R inhibitor in the management of liver fibrosis.
Authors
- Qixin Zhao (ORCID: https://orcid.org/0009-0007-1318-3829)
- Xinyue Liu (ORCID: https://orcid.org/0000-0002-0934-4155)
- Bingwen Zhu
- Tao Bi (ORCID: https://orcid.org/0000-0001-8121-3478)
- Zengjin Liu (ORCID: https://orcid.org/0009-0007-1746-8274)
- Lei Chen (ORCID: https://orcid.org/0009-0003-4906-5163)
- Yingcheng Yang
- Xiyu Dai
- Chunyan Liu (ORCID: https://orcid.org/0000-0003-4322-3063)
Institutions
- Southwest Medical University (CN)
- Affiliated Hospital of Southwest Medical University (CN)
- First Affiliated Hospital of Sichuan Medical University (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Journal of Translational Medicine
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1186/s12967-025-07362-w
- Citations
- 1
- Primary Topic
- Liver physiology and pathology
- Type
- article
- Field-Weighted Citation Impact
- 1.32